^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ARRY-382

    i
    Other names: ARRY-382, ARRY 382
    Associations

    News

    Trials
    Company:
    BMS, Pfizer
    Drug class:
    CSF-1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=82, Terminated, Pfizer | Completed --> Terminated; Study was halted prematurely due to insufficient efficacy. Not due to safety reasons.
    Trial termination • Combination therapy • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • ARRY-382
    3years
    A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=82, Completed, Pfizer | Phase classification: P1/2 --> P1b/2
    Clinical • Phase classification • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • ARRY-382
    4years
    A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=82, Completed, Array BioPharma | Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Oct 2019 | Trial primary completion date: Apr 2020 --> Oct 2019
    Clinical • Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • ARRY-382